Mitochondrial transfer: A comprehensive analysis of mechanistic insights, preclinical applications, and technological innovations

Every cell in the body relies on mitochondria—often called the cell's power plants—to generate energy and regulate survival. When mitochondria malfunction, diseases ranging from neurodegeneration to heart failure can follow. This comprehensive review, published in Neural Regeneration Research, synthesizes current knowledge on a striking biological phenomenon: the active transfer of mitochondria between cells, either to rescue damaged neighbors or, in some contexts, to propagate disease. The authors examine the multiple physical routes cells use to ship mitochondria (including tunneling nanotubes, extracellular vesicles, and gap junctions), the molecular machinery that controls cargo loading and docking, and the signaling cues that trigger or suppress transfer. They then survey preclinical evidence showing therapeutic mitochondrial transfer can restore function in models of stroke, cardiac ischemia, and metabolic disease. Finally, the review maps emerging biotechnologies—from engineered donor cell lines to nanoparticle-mediated delivery—designed to harness transfer therapeutically. The overarching message is that mitochondrial transfer is not a biological curiosity but a conserved, regulatable intercellular communication channel with substantial translational potential.

• Multiple distinct transfer routes are catalogued—tunneling nanotubes (TNTs), extracellular vesicles (EVs), gap junctions, cell fusion, and exopher-like structures—each with distinct cargo specificity, distance range, and regulatory controls, suggesting the cell deploys different mechanisms depending on metabolic context and injury severity.
• Preclinical models across neurological (stroke, TBI), cardiac (ischemia-reperfusion), and metabolic (diabetes, muscle atrophy) disease consistently report that exogenous mitochondrial transfer rescues recipient-cell ATP production, reduces oxidative stress markers, and attenuates apoptosis, though effect magnitudes vary widely by model and delivery method.
• Technological innovations reviewed include mitochondria-loaded nanocarriers, CRISPR-engineered donor cells expressing enhanced Miro1 surface anchors, and stem-cell platforms pre-conditioned to upregulate transfer efficiency—approaches aimed at overcoming the low yield and immunogenicity barriers that currently limit clinical translation.

This is a narrative/systematic review article, not a primary experimental study. The authors searched the literature on mitochondrial transfer mechanisms, preclinical therapeutic applications, and delivery technologies, then synthesized findings across in vitro, ex vivo, and animal-model studies. No original patient cohort, randomized trial, or pre-registered protocol is described; the scope is explicitly comprehensive and mechanistic rather than meta-analytic with pooled effect sizes.

As a review without formal meta-analytic weighting, publication bias toward positive preclinical results cannot be excluded, and heterogeneity across model systems makes it impossible to derive unified efficacy estimates. The preponderance of evidence comes from rodent or cell-culture models; human in vivo data on therapeutic mitochondrial transfer remain extremely sparse, leaving pharmacokinetics, immunological fate of donor mitochondria, and long-term safety unresolved. The next clarifying experiments would include standardized quantification protocols for transfer efficiency across labs and first-in-human dose-escalation studies using well-characterized allogeneic mitochondrial preparations.

This review serves as the mechanistic backbone for several articles in the corpus. It directly extends [§27] and [§28], which address specific intercellular mitochondrial transfer events—astrocyte-to-neuron rescue in Alzheimer's disease and EV-mediated mitochondrial reprogramming of T-helper cells in asthma, respectively—by providing the broader mechanistic and technological framework within which those findings sit. The CD38-Miro1 axis dysfunction described in [§27] is a concrete instantiation of the regulatory machinery this review catalogues, making the two articles mutually illuminating. It parallels [§71], which examines mitochondrial dysfunction in polycystic kidney disease through a disease-specific rather than transfer-focused lens, sharing the underlying premise that mitochondrial competence is a determinant of organ pathology. The review also contextualizes mitophagy-focused studies such as [§115] and [§136] by positioning mitophagy and mitochondrial transfer as complementary quality-control strategies: cells either degrade defective organelles or export/import them, and understanding when each pathway dominates is essential for therapeutic design.

• Dysfunction of the CD38-Miro1 Axis Disrupts Astrocyte-neuron Mitochondrial Transfer in Alzheimer's Disease: Mechanisms and Therapeutic Restoration
  Directly instantiates one transfer axis (CD38-Miro1, astrocyte-to-neuron) reviewed here; comparing them shows how a single mechanistic node from the review manifests in Alzheimer's disease pathology.
• Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma
  Demonstrates EV-mediated mitochondrial transfer in an immune context (asthma), offering a non-neural, non-cardiac case study that tests the generalizability of the transfer routes catalogued in this review.
• The Role of Mitochondria in Polycystic Kidney Disease
  Covers mitochondrial dysfunction in polycystic kidney disease without focusing on transfer, providing a useful contrast: same organelle, different therapeutic angle (intrinsic mitochondrial quality vs. intercellular rescue).
• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Focuses on mitochondrial RNA release as a driver of inflammation and senescence—a parallel extracellular mitochondrial-content signaling mechanism—highlighting that mitochondrial cargo transfer has both beneficial (this review) and potentially detrimental (mtRNA-mediated inflammation) faces.
• Mito_Plot: open-source pipeline for quantification and visualization of mitochondrial DNA heteroplasmy
  Presents an open-source pipeline for quantifying mitochondrial DNA heteroplasmy, a methodological tool directly relevant to validating donor-versus-recipient mitochondrial identity in transfer experiments described in this review.